CellSource Co., Ltd. (4880.T) Comparison with companies in other sectors?

CellSource Co., Ltd. has a share price of 19.82M. You can analyze CellSource Co., Ltd. (4880.T) competitors across different market sectors through stock heatmaps.

What are 4880.T's NET and operating margins?

CellSource Co., Ltd. (4880.T) operating margin is around -0.03, and net profit margin is approximately 0.01 as of the latest reports.

In what way does 4880.T's earnings per share (EPS) trend reflect its financial momentum?

CellSource Co., Ltd. (4880.T) EPS is -2.57 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for CellSource Co., Ltd. is -264.20, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for CellSource Co., Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for CellSource Co., Ltd. like P/E which is 276.90, P/B which is 2.28, and PEG which is -3.48. Compare them with sector averages to evaluate if the stock is priced fairly.

CellSource Co., Ltd.

4880.T•JPX

Healthcare

Biotechnology

¥679.00

¥-16.00(-2.30%)

CellSource Co., Ltd. (4880.T) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-2.57

P/E Ratio

-264.20

ROE

0.008%

Net Margin

0.01%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$13.45B

Shares OutstandingTotal number of shares issued

$19.82M

Book Value/ShareNet worth per share

$297.54

Revenue/ShareAnnual revenue per share

$203.48

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-2.57

Net MarginNet income as percentage of revenue

1.21%

Operating MarginOperating income as percentage of revenue

-3.45%

ROEReturn on shareholders' equity

0.80%

ROAReturn on total assets

0.71%

ROCEReturn on capital employed

-2.14%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

Cash/ShareCash and equivalents per share

$215.26

FCF YieldFree cash flow as percentage of market cap

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$5.00

Dividend YieldAnnual dividend as percentage of stock price

0.74%

Financial Ratios Analysis data is not available for 4880.TFinancial Ratios Analysis details for 4880.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 4880.TSector Benchmarking details for 4880.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for CellSource Co., Ltd. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of CellSource Co., Ltd.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account CellSource Co., Ltd.'s unique business strengths and challenges.

Key Financial Metrics for CellSource Co., Ltd.

For CellSource Co., Ltd., essential financial indicators include EPS -2.57, PE -264.20, and ROE 0.008. These key ratios reveal insights into CellSource Co., Ltd.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare CellSource Co., Ltd. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of CellSource Co., Ltd.

Metrics like Net Margin 1.21% and ROA 0.71% shed light on how well CellSource Co., Ltd. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether CellSource Co., Ltd. can sustain its operations and continue growing in the future.

Valuation and Market Position of CellSource Co., Ltd.

Using ratios such as P/B Ratio 2.28 and PEG Ratio -3.48, investors can assess whether CellSource Co., Ltd. is appropriately valued based on its financials and growth potential. These figures, combined with CellSource Co., Ltd.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for CellSource Co., Ltd.

Financial health indicators, such as Debt/Equity Ratio 0.009 and Cash Flow -, provide a snapshot of CellSource Co., Ltd.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like CellSource Co., Ltd., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for CellSource Co., Ltd.

Investing in CellSource Co., Ltd. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at CellSource Co., Ltd. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;